PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study
- PDF / 1,019,238 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 54 Downloads / 141 Views
ORIGINAL ARTICLE
PD-L1 and HER2 Expression in Gastroesophageal Cancer: a Matched Case Control Study Andrea Beer 1,2 & Hossein Taghizadeh 2,3 & Ana-Iris Schiefer 1,2 & Hannah C. Puhr 2,3 & Alexander K. Karner 2,3 & Gerd Jomrich 2,4 & Sebastian F. Schoppmann 2,4 & Renate Kain 1,2 & Matthias Preusser 2,3 & Aysegül Ilhan-Mutlu 2,3 Received: 5 October 2019 / Accepted: 23 April 2020 # The Author(s) 2020
Abstract Immunotherapy with check-point inhibitors serves as a promising treatment strategy in patients with upper gastrointestinal (GI) tumors. Human epidermal growth factor receptor 2 (HER2) is the only identified therapeutic target in upper GI tumors, whose potential interaction with programmed death-ligand 1 (PD-L1) is unknown. The aim of this study was the investigation of PD-L1 and HER2 in upper GI tumors. We retrospectively identified patients with HER2 positive gastroesophageal cancers and matched them with a HER2 negative group. We investigated the tumor specimens for HER2 status and PD-L1 expression, with the following assessments being performed: i) staining of tumor cells in terms of tumor proportion score (TPS), ii) staining for tumorassociated immune cells (TAIs), iii) interface pattern and iv) combined positive score (CPS). Both HER2 positive and negative group consisted of 59 patients. Expression of PD-L1 in TAIs and interface pattern were associated with a favorable outcome (p = 0.02, HR = 0.8; p = 0.04, HR = 0.39; respectively) in patients with localized disease, whereas TPS was associated with an unfavorable outcome in patients with advanced tumor (p = 0.02, HR = 1.4). These effects were HER2 independent. PD-L1 expression in its different assessment is equally observed in HER2 positive and negative patients. Future studies will show whether dual inhibition of HER2 and PD-L1 improves survival of this selected patient population. Keywords Gastroesophageal tumor . Esophageal tumor . Gastroesophageal junction tumor . Gastric tumor . PD-L1 . HER2 . Immunotherapy . TPS . CPS
Introduction Précis Expression of PD-L1 is equally observed in HER2 positive and negative patients. Future studies will show whether dual inhibition of HER2 and PD-L1 improves survival of this selected patient population. Electronic supplementary material The online version of this article (https://doi.org/10.1007/s12253-020-00814-2) contains supplementary material, which is available to authorized users. * Aysegül Ilhan-Mutlu [email protected] 1
Department of Pathology, Medical University of Vienna, Wien, Austria
2
Comprehensive Cancer Center Vienna, Upper GI Tumors Unit, Medical University of Vienna, Wien, Austria
3
Department of Medicine I, Clinical Division of Oncology, Upper Gastrointestinal Tumors Unit, Medical University of Vienna, Wien, Austria
4
Department of Surgery, Medical University of Vienna, Wien, Austria
Gastric cancer is the fourth most commonly diagnosed cancer and the second most common cause of cancer related deaths worldwide [1]. Most patients present with inoperable advanced or metastatic dise
Data Loading...
